Clinical trials
Rectal Adenocarcinoma clinical trials
Below are recruiting rectal adenocarcinoma clinical trials, each written for real people, not researchers. We’re tracking 55 recruiting studies, each written for real people, not researchers, below.
Recruiting studies
- NCT06843434RecruitingPhase 2
Study of two immunotherapy drugs for rectal cancer
This trial tests a combination of two immunotherapy drugs, botensilimab and balstilimab, for people with newly diagnosed rectal adenocarcinoma that has not spread. The goal is to see if this treatment can shrink the tumor before surgery.
Basking Ridge, New JerseyAges 18 years+ - NCT05672524RecruitingPhase 2
Tucatinib plus trastuzumab for HER2-positive rectal cancer
This Phase 2 study tests whether tucatinib combined with trastuzumab can slow or shrink rectal cancer that is HER2-positive and has certain genetic tumor features. If you qualify, you may benefit from a targeted treatment approach aimed at the HER2 pathway.
Basking Ridge, New JerseyAges 18 years+ - NCT06266832RecruitingPhase 2
Short-course radiation with immunotherapy and chemo for rectal cancer
This trial tests a combination of short-course radiation, an immunotherapy drug (adebrelimab), and chemotherapy (CAPEOX) before surgery to help preserve the rectum in people with MSS/pMMR ultra-low rectal cancer. The goal is to shrink the tumor enough to avoid removing the rectum.
Hangzhou, ZhejiangAges 18 years+ - NCT07407465RecruitingPhase 2
Study of a new drug combo for advanced HER2-positive colorectal cancer
This trial tests a combination of three drugs (trastuzumab deruxtecan, capecitabine, and bevacizumab) as the first treatment for people with HER2-positive colorectal cancer that has spread or cannot be removed by surgery. The goal is to see if this combination can shrink tumors and help patients live longer.
LyonAges 18 years+ - NCT05482516RecruitingPhase 3
Testing blood test–guided treatment for GI cancers in remission
This Phase 3 study tests whether giving treatment based on a positive blood test for “minimal cancer signals” (ctDNA) can help people with certain GI cancers stay cancer-free longer. It focuses on people who have finished curative-intent therapy and currently have no visible disease on scans, but their blood test is still positive.
Washington D.C., District of ColumbiaAges 18 years+ - NCT07198165RecruitingPhase 2
Short radiation followed by chemo plus bevacizumab with or without immunotherapy for rectal cancer
This trial tests whether adding an immunotherapy drug (PD-1 inhibitor) to standard chemoradiation and targeted therapy improves outcomes for locally advanced rectal cancer. It is for patients who have not had prior treatment and do not have certain genetic markers (BRAF mutation or MSI-H).
ShanghaiAges 18–75 - NCT07669220RecruitingPhase 2
Short radiation, immunotherapy, and chemo for advanced rectal cancer
This trial compares a new treatment approach—short-course radiation followed by an immunotherapy drug (PD-1 inhibitor) and chemotherapy (FOLFOX)—to the standard long-course chemoradiation for people with a specific type of advanced rectal cancer that is pMMR/MSS. The goal is to see if the shorter treatment works as well or better.
GuangzhouAges 18–75 - NCT06569368RecruitingPhase 2
Metronidazole with rectal cancer treatment
This trial tests adding the antibiotic metronidazole to standard pre-surgery therapy for locally advanced rectal cancer. The goal is to see if changing the bacteria in your gut can make the cancer treatment work better.
Houston, TexasAges 18 years+ - NCT04703101RecruitingPhase 1
Short radiation plus chemo for stage II–III rectal cancer
This trial tests a short course of radiation therapy combined with chemotherapy for people with stage II or III rectal cancer. It’s designed to see whether this approach is safe and effective before or around cancer surgery.
Los Angeles, CaliforniaAges 18 years+ - NCT06402864RecruitingPhase 3
Internal radiation for rectal preservation in intermediate rectal cancer
This study is testing whether a special internal radiation treatment (contact X-ray brachytherapy) can help people with intermediate-stage rectal cancer avoid surgery and keep their rectum intact. It is for patients who are also receiving mFolfirinox chemotherapy.
Avignon, FranceAges 18–99 - NCT07143487Recruiting
Family communication after genetic testing for colon cancer
This trial studies how patients with newly diagnosed colon cancer share genetic test results with their family members. It aims to improve communication and support after learning about hereditary risk.
Anchorage, AlaskaAges 18 years+ - NCT03594630RecruitingEarly Phase 1
Watchful waiting then chemotherapy before surgery for rectal cancer
This trial studies whether a period of active surveillance (watching closely) and chemotherapy before surgery can improve outcomes for people with stage II–III rectal cancer. You would also receive standard chemo-radiation if you qualify, then proceed to surgery.
Houston, TexasAges 18 years+ - NCT05081024Recruiting
Blood test biomarker to help preserve organs in rectal cancer
This study looks at a blood test (ctDNA, a way to detect cancer DNA in the bloodstream) to help doctors choose treatment that may spare organs for people with stage II–III rectal cancer. You may be followed to see how well the blood test can guide treatment decisions.
Portland, OregonAges 18 years+ - NCT02107105Recruiting
Study how surgery affects life quality in rectal cancer
This trial studies how surgical treatment for rectal cancer affects patients’ quality of life and other day-to-day impacts. It may help doctors understand what to expect after surgery and how to better support patients.
Houston, TexasAges 18 years+ - NCT07292298RecruitingPhase 2
Rectal cancer brachytherapy after treatment to avoid surgery
This trial tests a special type of internal radiation (brachytherapy) for people with low-lying rectal cancer that did not fully go away after standard chemoradiation and chemotherapy. The goal is to shrink the remaining tumor enough to avoid major surgery like removing the rectum or colostomy.
Aurora, ColoradoAges 18–100 - NCT07595874RecruitingPhase 2
New Immunotherapy Drugs Before Surgery for Advanced Colorectal Cancer
This trial tests two immunotherapy drugs (botensilimab and balstilimab) given before surgery to treat advanced colorectal cancer that can be removed. The goal is to help the immune system fight cancer cells and improve outcomes after surgery.
Goodyear, ArizonaAges 18 years+ - NCT06050447Recruiting
Study on treatment results for colorectal cancer
This study looks at factors that affect outcomes in people with colorectal cancer who have surgery as their main treatment. It aims to help doctors understand how to improve care.
Kaliningrad, Kaliningrad OblastAges 18 years+ - NCT06952101Recruiting
Personalized treatment for rectal cancer to save the organ
This trial tests a personalized, step-by-step approach for rectal cancer that aims to avoid surgery and preserve the rectum. It is for patients whose tumor has shrunk significantly after chemoradiation, or who have early-stage high-risk cancer removed during a scope procedure.
Candiolo, TurinAges 18 years+ - NCT06780787RecruitingPhase 2
Study of chemo plus immunotherapy for localized rectal cancer before surgery
This trial tests a combination of chemotherapy (FOLFOX) and two immunotherapies (botensilimab and balstilimab) before surgery for patients with localized rectal cancer. It aims to see if adding immunotherapy helps shrink the tumor and improve outcomes.
Duarte, CaliforniaAges 18 years+ - NCT06540027Enrolling by invitation
Minimally invasive surgery for rectal cancer inflammation
This study looks at how different types of surgery (open, laparoscopic, or robotic) affect inflammation throughout the body in people with rectal cancer. It may help doctors understand which approach is gentler on your immune system.
IstanbulAges Any age - NCT07104604RecruitingPhase 2
New combo before surgery for low rectal cancer
This trial tests a new combination of treatments (radiation, immunotherapy, and two chemotherapy drugs) given before surgery for people with a specific type of locally advanced rectal cancer that is close to the anus. The goal is to see if this approach is safe and effective.
Shantou, GuangdongAges 18–75 - NCT06328361Recruiting
Avoiding surgery for rectal cancer after good response to treatment
This trial tests a new approach: after initial treatment (like chemo or radiation), people with rectal cancer who have a complete response may be able to avoid surgery. Instead, they are monitored closely to see if the cancer stays away.
TallinnAges 18 years+ - NCT06834126RecruitingPhase 1
Papaverine with radiation for advanced rectal cancer
This trial tests if adding papaverine (a drug) to radiation therapy can help people with locally advanced rectal cancer avoid surgery and keep their rectum. It is for patients who have already had chemotherapy and want a non-surgical approach.
Duarte, CaliforniaAges 18 years+ - NCT06997497RecruitingPhase 3
Study of Calderasib with other drugs for colorectal cancer
This trial tests a new drug called Calderasib combined with targeted therapy or chemotherapy for people with advanced colorectal cancer that has a specific genetic change (KRAS G12C mutation). It may be an option for those who have not had prior treatment for advanced disease.
Los Angeles, CaliforniaAges 18 years+
Hear when a new Rectal Adenocarcinoma trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.
Rectal Adenocarcinoma trials by city
Studies with a site in or near these metro areas.
Rectal Adenocarcinoma trials by state
Studies with a site anywhere in these states.
Common questions
- Are there clinical trials for rectal adenocarcinoma?
- Yes. Clin2 currently lists 55 recruiting rectal adenocarcinoma studies from the U.S. registry, each rewritten for real people, not researchers, so you can see what it’s testing and who it’s for.
- How do I know if I qualify for a rectal adenocarcinoma trial?
- Each study lists its eligibility criteria — rules about age, diagnosis, and prior treatments. On every Clin2 trial page we explain these in words written for real people and offer a short, optional pre-screen for a fit read. The study team makes the final decision.
- Does it cost anything to join a rectal adenocarcinoma trial?
- Using Clin2 is always free. Many trials cover the cost of the study treatment and related visits; some reimburse travel. The study team explains exactly what’s covered before you decide.
Related conditions
Clin2 helps you find and understand clinical trials and does not provide medical advice. Study data comes from ClinicalTrials.gov. Talk with your doctor about whether a specific trial is right for you.